Successful management of refractory diabetic gastroparesis with long‐term Aprepitant treatment. Issue 10 (October 2017)

• Record Type: Journal Article
• Authors: Fountoulakis, N.; Dunn, J.; Thomas, S.; Karalliedde, J.
• Is Part Of: Diabetic medicine. Volume 34:Issue 10(2017)
• Page Start: 1483
• Page End: 1486
• Publication Date: 2017-10
• Subjects: Diabetes -- Periodicals; 616.462
• DOI: 10.1111/dme.13413
• Languages: English
• ISSNs: 0742-3071

Abstract

Abstract: Background: People with gastroparesis who develop treatment‐resistant (refractory) disease pose a difficult challenge, especially in the setting of end‐stage renal disease (ESRD) or post pancreas transplant. Aprepitant (a neurokinin‐receptor antagonist) is licensed for the short‐term treatment of chemotherapy‐induced nausea. There is lack of information on its long‐term efficacy and safety in people with diabetic gastroparesis. Case report: Case 1 was 73‐year‐old man with Type 2 diabetes of 25 years' duration and ESRD requiring dialysis. He was referred to our unit as his severe symptoms of gastroparesis had failed to respond to multiple medications and resulted in frequent hospital admissions. Aprepitant, which can be used in ESRD, resulted in significant improvement in his symptoms of nausea and vomiting within weeks, and he remained on this long term (18 months) with continued benefits and had no further gastroparesis‐related hospital admissions. Case 2 was a 44‐year‐old man with Type 1 diabetes of 41 years' duration with a history of severe hypoglycaemic events that required a pancreas transplant. Despite normoglycaemia, his symptoms of gastroparesis persisted and failed to respond to multiple medications and frequent botulinum toxin injections. He was commenced on aprepitant with significant improvement in symptoms and has remained on treatment for 12 months with sustained benefits. Conclusion: We describe two cases in which long‐term aprepitant treatment proved effective in alleviating severe symptoms of gastroparesis that had failed to respond to conventional first‐line medical treatments. Our cases highlight the need for novel treatments for managing refractory diabetic gastroparesis. What's new?: The cases in this report illustrate the clinical challenges in managing treatment‐resistant diabetic gastroparesis in the setting of end‐stage renal disease and post transplant. There are no previous case reports or data on the long‐term effects and safety of aprepitant (a neurokinin‐receptor antagonist) in diabetic gastroparesis. We report the sustained benefits (> 12 months) and safety of aprepitant in refractory gastroparesis. Our cases highlight the need for increased awareness of the contraindications and risks of medications used in gastroparesis. The cases we present and emerging data support the further evaluation of aprepitant as a treatment for refractory diabetic gastroparesis.